MED — Medifast, Inc.

Summary of Medifast Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $76.4 million, down 27.6% year-over-year, but in line with guidance.
• Earnings Per Share (EPS): Net loss of $3.1 million, or $0.28 per diluted share, compared to a net income of $2.5 million, or $0.22 per share, in Q2 2025.
• Active Earning Coaches: Approximately 11,700, a decrease of 48.7% year-over-year.
• Revenue per Active Earning Coach: Increased by 41.0% year-over-year to $6,529, the highest since Q2 2022.
• Gross Profit: $53.4 million, down 30.3% year-over-year; gross profit margin at 69.9%.
• SG&A Expenses: Decreased by 25.7% year-over-year to $57.7 million.
• Cash Position: Ended the quarter with $169.8 million in cash and investments, with no debt.

2. Strategic Updates and Business Highlights

• Leadership Change: Nick Johnson addressed the call as the new CEO, emphasizing a strategic transition to metabolic health.
• 3.0 Strategy: Introduction of the new consumer brand, Trilivy, aimed at expanding offerings and improving coach productivity.
• Metabolic Health Focus: The company aims to address the significant market of U.S. adults who are metabolically unhealthy, leveraging a science-backed, coach-guided system.
• New Initiatives: Launched the Medifast Metabolic Health Institute to support research and education in metabolic health.
• Enhanced Compensation Plan: Aimed at developing Executive Directors to drive sustainable growth.

3. Forward Guidance and Outlook

• Q3 2026 Revenue Guidance: Expected to range from $60 million to $80 million, with EPS loss projected between $0.15 and $0.65.
• Full Year 2026 Revenue Guidance: Anticipated to range from $270 million to $300 million, with a loss per share between $0.25 and $1.75.
• Profitability Target: Management aims to return to profitability by Q4 2026, supported by the new product line and cost-saving initiatives.

4. Bad News, Challenges, or Points of Concern

• Declining Active Coaches: A significant drop in the number of active earning coaches, attributed to competition from GLP-1 medications in the weight loss market.
• Revenue Decline: Despite improved productivity metrics, overall revenue continues to decline due to fewer active coaches.
• Loss from Operations: Increased to $4.3 million, reflecting challenges in maintaining profitability amidst declining sales volumes.
• Market Competition: The rapid adoption of GLP-1 medications poses a competitive threat to traditional weight loss programs.

5. Notable Q&A Insights

• Catalyst Program: Management highlighted the Catalyst program's potential for cost savings but did not provide specific quantifications, indicating further details will be shared in Q3.
• Path to Profitability: The Catalyst program is one of several levers to achieve profitability, alongside expected revenue stabilization and new product launches.
• Coach Transition to Trilivy: Positive reception from coaches regarding the new brand and product line, with no major issues reported in the transition from OPTAVIA to Trilivy.

Overall, Medifast is navigating a challenging environment with a focus on strategic initiatives aimed at revitalizing growth and returning to profitability while facing significant headwinds from market competition and declining active coach numbers.